Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

NCT02290340 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02290340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02290340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
January 13, 2015
Completion date
September 28, 2016
Enrollment
151 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus